Real-Life Analysis Evaluating 1000 N0/Nlmi Estrogen Receptor (ER)+ Breast Cancer Patients for Whom Treatment Decisions Incorporated the 21-Gene Recurrence Score (RS) Result: Clinical Outcomes with Median Follow Up of 9 Years

Prof. Salomon M. Stemmer
Head, Research Unit I Institute of Oncology I Davidoff Center, Rabin Medical Center

Phase Ill TAILORx Trial Results in Node Negative, Hormone-Receptor Positive, HER2 Negative Breast Cancer: Implications for Clinical Practice

Lori J. Goldstein, MD, Fasco
Professor, Medical Oncology I Director, Naomi and Phil Lippincott Breast Evaluation Center I Chief, Breast Service I Deputy Associate Director of Clinical Research I Fox Chase Cancer Center Temple Health, Philadelphia, USA

Real World Evidence of OncotypeDX Use and Outcomes in the US SEER Registry to Complement the Results Observed in randomized Trials

Steven Shak, MD
Chief Scientific Officer at Genomic Health Executive Vice President of Research and Development Genomic Health I Inc.Redwood City, California

Case Studies- Tumor Board Discussion

Case 1 Moderator:

Prof. Moshe lnbar
Senior Oncology Consultant I Assuta Medical Centers

Case 2 Moderator:

Dr. Noa Efrat Ben-Baruch
Head, Israeli Breast Cancer Group I Head, Department of Oncology I Kaplan Medical Center

Panel:

Prof. Bella Kaufman
Head, Breast Oncology Institute I Sheba Medical Center
Prof. Rinat Yerushalmi
Head, Breast Cancer Unit I Davidoff Center, Rabin Medical Center
Dr. Shani Paluch-Shimon
Director, Breast Oncology Unit I Director I Shaare Zedek Medical Center
Dr. Amir Sonnenblick
Head, Breast Cancer Unit The Oncology Division I Tel Aviv Sourasky Medical Center